Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
NCT06559150Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2024
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in Non-cystic fibrosis bronchiectasis (NCFB) comparing Treatment Arm 1: Ensifentrine with Treatment Arm 2: Placebo (2 arms). Primary endpoint: Rate of protocol-defined pulmonary exacerbations at 52 weeks. Started Sep 2024; status: recruiting.
02
Drugs
ensifentrine
03
Conditions
Non-cystic fibrosis bronchiectasis (NCFB)
Beyond the preview
Go deeper on NCT06559150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06559150.